CSIMarket
 


Zogenix Inc   (ZGNX)
Other Ticker:  
 

Zogenix Inc 's Leverage Ratio

ZGNX's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 6.17%, Leverage Ratio fell to 1.62, below the Zogenix Inc 's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2021, 460 other companies have achieved lower Leverage Ratio than Zogenix Inc in the IV Quarter 2021. While Leverage Ratio total ranking has deteriorated compared to the third quarter 2021 from 2710 to 3114 .

Explain Leverage Ratio?
Who are ZGNX Customers?
What are ZGNX´s Total Liabilities?


ZGNX Leverage Ratio (Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Sep 30 2020)
III. Quarter
Y / Y Equity Change -57.6 % -44.64 % -39.43 % 31.1 % 68.44 %
Y / Y Total Liabilities Change 7.25 % 81.84 % 70.85 % 53.49 % 59.01 %
Leverage Ratio MRQ 1.62 1.22 0.98 0.81 0.64
ZGNX's Total Ranking # 3114 # 2710 # 1008 # 873 #
Seq. Equity Change -20.21 % -17.8 % -15.07 % -23.88 % 4.18 %
Seq. Total Liabilities Change 6.17 % 2.05 % 2.9 % -3.8 % 80.01 %



Leverage Ratio forth quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 461
Healthcare Sector # 929
Overall Market # 3114


Leverage Ratio Statistics
High Average Low
294.97 10.81 0.19
(Mar 31 2012)   (Sep 30 2018)




Financial Statements
Zogenix Inc 's Equity $ 179 Millions Visit ZGNX's Balance sheet
Zogenix Inc 's Total Liabilities $ 290 Millions Visit ZGNX's Balance sheet
Source of ZGNX's Sales Visit ZGNX's Sales by Geography


Cumulative Zogenix Inc 's Leverage Ratio

ZGNX's Leverage Ratio for the trailling 12 Months

ZGNX Leverage Ratio

(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
(Mar 31 2021)
I. Quarter
(Sep 30 2020)
III. Quarter
Y / Y Equity TTM Growth -57.6 % -44.64 % -39.43 % 31.1 % 68.44 %
Y / Y Total Liabilities TTM Growth 7.25 % 81.84 % 70.85 % 53.49 % 59.01 %
Leverage Ratio TTM 1.09 0.86 0.67 0.52 0.49
Total Ranking TTM # 200 # 22 # 19 # 18 #
Seq. Equity TTM Growth -20.21 % -17.8 % -15.07 % -23.88 % 4.18 %
Seq. Total Liabilities TTM Growth 6.17 % 2.05 % 2.9 % -3.8 % 80.01 %


On the trailing twelve months basis Due to the net new borrowings of 6.17% during the trailing twelve months finishing in the IV Quarter 2021, cumulativeLeverage Ratio improved to 1.09, above the Zogenix Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 35, during the past 12 months, other companies have achieved lower Leverage Ratio than Zogenix Inc . While Leverage Ratio total ranking has deteriorated during the twelve months ending in the IV Quarter 2021, compared to the prior period, from 22 to 200.

Explain Leverage Ratio?
Who are ZGNX Customers?
What are ZGNX´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 36
Healthcare Sector # 73
Within the Market # 200


trailing twelve months Leverage Ratio Statistics
High Average Low
0.62 0.14 0.02
(Dec 31 2021)  




Companies with similar Leverage Ratio in the quarter ending Dec 31 2021, within Major Pharmaceutical Preparations Industry Leverage RatioDec 31 2021 MRQ Total LiabilitiesDec 31 2021 MRQ Equity
Eli Lilly And Company  4.16 $ 38,093.100  Millions$ 9,154.800  Millions
Cv Sciences Inc   4.08 $ 14.461  Millions$ 3.543  Millions
Clene Inc   4.01 $ 50.466  Millions$ 12.597  Millions
Acura Pharmaceuticals inc  3.83 $ 0.682  Millions$ 0.178  Millions
Global Blood Therapeutics Inc.  3.78 $ 742.798  Millions$ 196.410  Millions
Dynavax Technologies Corporation  3.52 $ 782.556  Millions$ 222.374  Millions
Jaguar Health inc   3.51 $ 41.654  Millions$ 11.853  Millions
Apellis Pharmaceuticals Inc   3.44 $ 683.103  Millions$ 198.662  Millions
Ainos Inc   3.35 $ 34.185  Millions$ 10.197  Millions
Agile Therapeutics Inc  3.24 $ 30.062  Millions$ 9.271  Millions
Exicure Inc   3.23 $ 36.319  Millions$ 11.232  Millions
Celularity Inc   3.17 $ 314.710  Millions$ 99.418  Millions
Baudax Bio Inc   3.03 $ 40.051  Millions$ 13.226  Millions
Heron Therapeutics Inc   2.94 $ 228.136  Millions$ 77.570  Millions
Maravai Lifesciences Holdings Inc   2.92 $ 1,592.566  Millions$ 545.361  Millions
Beyondspring Inc   2.90 $ 60.725  Millions$ 20.923  Millions
Nanobiotix S a   2.80 $ 83.976  Millions$ 30.005  Millions
Societal Cdmo Inc   2.79 $ 117.198  Millions$ 42.064  Millions
Novan Inc   2.76 $ 50.641  Millions$ 18.319  Millions
China Pharma Holdings Inc   2.76 $ 16.632  Millions$ 6.018  Millions
Teva Pharmaceutical Industries Limited  2.75 $ 30,939.000  Millions$ 11,244.000  Millions
Adc Therapeutics Sa  2.72 $ 451.884  Millions$ 166.088  Millions
Liminal Biosciences Inc   2.72 $ 70.604  Millions$ 25.953  Millions
Athersys Inc  2.68 $ 43.815  Millions$ 16.369  Millions
Phibro Animal Health Corporation  2.55 $ 609.664  Millions$ 239.294  Millions
Avalo Therapeutics Inc   2.47 $ 57.019  Millions$ 23.082  Millions
Fibrogen Inc   2.46 $ 564.675  Millions$ 229.113  Millions
Infinity Pharmaceuticals Inc   2.42 $ 52.234  Millions$ 21.571  Millions
Cytokinetics Incorporated  2.39 $ 582.593  Millions$ 243.863  Millions
Ionis Pharmaceuticals Inc  2.38 $ 1,839.953  Millions$ 771.737  Millions

Date modified: 2022-03-03T13:44:16+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com